The synthesis team at Chemveda completing the synthesis of compounds for evaluation, December 2025
Colin Suckling – Rostra Therapeutics Ltd, United Kingdom
Dr. Shridhar Narayanan – Foundation for Neglected Diseases Research, India
Elaine Bignell – University of Exeter, United Kingdom
Brahmaiah Dabbugoddu – Chemveda Life SciencesPvt. Ltd., India
Dr Sashikumar Menon – Institute of Advanced Research in Interdisciplinary Sciences (Therapeutic Drug Monitoring Laboratory), India
India and neighbouring countries
Microbial Pathogenesis
Candida auris and others
Rostra has a novel technology platform developed at the University of Strathclyde, that can be applied to make new drugs. We want to use this to develop new medicines to address serious infectious diseases caused by fungi that, in India and other global markets, have become untreatable by existing antifungal drugs because the infections have developed antimicrobial resistance. The result of this resistance is that patients who could be effectively treated previously are now incurable, leading to considerable suffering and cost, an increase in deaths and an increased burden on the healthcare system. To ensure that we develop the medicines appropriate for patients in India, we will work with local Indian scientific and commercial partners to focus on diseases with the highest impact. We will build a network of Indian partners to allow for continuous and full development of our novel antifungal therapeutic from early laboratory work, through studies in patients and onto patient access in India and surrounding countries with similar health needs. This project will bring together centres of scientific and developmental excellence from the UK and India in a true translational partnership to develop solutions to the problems of fungal antimicrobial resistance in India, and explore a new model of local development and access to maximise local healthcare priorities and patients needs.
